Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Cancer Biomarker | Research article

Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas

Authors: Bangbo Zhao, Qin Cheng, Hongtao Cao, Xingtong Zhou, Tianhao Li, Liangbo Dong, Weibin Wang

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

CA19–9 is one of the most widely used tumor markers in biliary-pancreatic diseases. The measured value may not factually reflect the genuine CA19–9 level secreted by tumor, which affected by biliary obstruction. There is an urgent need of developing a correction formula of CA19–9 in biliary obstructive patients to guide clinical practice and avoid making improper clinical decision.

Methods

Clinical characteristics were collected among patients undergoing biliary drainage in our hospital between January 2014 and January 2019. By comparing the malignant and benign patients statistically, dynamic change trend of CA19–9 levels after biliary drainage was obtained. The correction formulas of CA19–9 were generated by means of linear regression.

Results

121 patients, including 102 malignant and 19 benign patients, were enrolled in this study. The baseline CA19–9 level of malignant patients is much higher than that of benign patients. Total bilirubin (TB) level was found to be not related with CA19–9 value (p = 0.109). The drop proportion of the average CA19–9 level in the malignant patients (39.2%, IQR -18.4-78.6%) was much lower than that in the benign patients (75.7%, IQR 58.1–86.6%) (p = 0.014). The correction formula, CA19–9_True = 0.63 × CA19–9_Measured - 20.3 (R² = 0.693, p<0.001), was generated based on the linear relation between CA19–9 after drainage and CA19–9 before drainage in malignant patients, which had similar diagnostic value with true CA19–9 value.

Conclusions

Quantitative correction formulas of CA19–9 considering the effect of biliary decompression was first proposed in this study, aiming to provide a more accurate CA19–9 level to make more accurate clinical decision and avoid making improper therapeutic schedule.

Available only for authorised users

Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem. 1982;257(23):14365–9. https://doi.org/10.1016/S0021-9258(19)45389-1.CrossRefPubMed

Gareth M-S, Taylor Mark A. Ca19–9 and pancreatic cancer: Is it really that good? J Gastrointest Oncol. 2012;3:88–9.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma, Version 1. 2019. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 8 Nov 2018.

Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26(5):474–9. https://doi.org/10.1053/ejso.1999.0925.CrossRefPubMed

Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009;198(3):333–9. https://doi.org/10.1016/j.amjsurg.2008.12.031.CrossRefPubMed

Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009;47(6):750–4. https://doi.org/10.1515/CCLM.2009.152.CrossRefPubMed

Ventrucci M, Pozzato P, Cipolla A, et al. Persistent elevation of serum CA 19–9 with no evidence of malignant disease. Dig Liver Dis. 2009;41:357–63.CrossRef

La'ulu Sonia L, Roberts William L. Performance characteristics of five automated CA 19–9 assays. Am J Clin Pathol. 2007;127:436–40.CrossRef

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Pancreatic Adenocarcinoma, Version 1. 2016. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 22 Mar 2016.

10.

Maithel Shishir K, Stephen M, Corrine W, et al. Preoperative CA 19–9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15(12):3512–20, Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma. https://doi.org/10.1245/s10434-008-0134-5.CrossRefPubMed

11.

Choon KY, Joo KH, Ho PJ, et al. Can preoperative CA19–9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol. 2009;24:1869–75.CrossRef

12.

Almadi Majid A, Othman A, Nahla A, et al. Clinical predictors of resectability of pancreatic adenocarcinoma. Saudi J Gastroenterol. 2013;19(6):278–85. https://doi.org/10.4103/1319-3767.121036.CrossRefPubMedPubMedCentral

13.

Shuji I, Shugo M, Windsor John A, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18:2–11.CrossRef

14.

Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Di. Sci. 2008;53:3213–7.

15.

Gaetano LG, Maria S, Rosario L, et al. Adjusting CA19–9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein. World J Gastroenterol. 2012;18:4150–5.CrossRef

16.

Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, et al. MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J Cancer. 2008;98(10):1675–81. https://doi.org/10.1038/sj.bjc.6604364.CrossRefPubMedPubMedCentral

17.

Naofumi U, Gao C, Tomoko Y, et al. Identification of a novel type of CA19-9 carrier in human bile and sera of cancer patients: an implication of the involvement in nonsecretory exocytosis. J Proteome Res. 2010;9:6345–53.CrossRef

18.

Valéry G, Sandrine B, Ghaffar M, et al. Rapid purification of human ductal cells from human pancreatic fractions with surface antibody CA19-9. Biochem Biophys Res Commun. 2004;320:27–33.CrossRef

19.

Engle Dannielle D, Hervé T, Rivera Keith D, et al. The glycan CA19–9 promotes pancreatitis and pancreatic cancer in mice. Science. 2019;364(6446):1156–62, The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. https://doi.org/10.1126/science.aaw3145.CrossRefPubMedPubMedCentral

20.

Nicolas S, Olivier F, Pablo O-D, et al. CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients. Pancreatology. 2018;18:666–70.CrossRef

21.

Werner H, Oliver S, Ulf H, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188–96.CrossRef

22.

Marta H-V, Luis B. Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer. Ann Transl Med. 2016;4:64.CrossRef

23.

Lu H, Fangfei N, Fang L, et al. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. Cancer Med. 2017;6(6):1181–91. https://doi.org/10.1002/cam4.1064.CrossRefPubMedPubMedCentral

24.

Melo Sonia A, Luecke Linda B. Kahlert Christoph et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82. https://doi.org/10.1038/nature14581.CrossRefPubMedPubMedCentral

25.

Yang Katherine S, Hyungsoon I, Seonki H, et al. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci Transl Med. 2017;9.

26.

Rhim Andrew D, Thege Fredrik I, Santana Steven M, et al. Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology. 2014;146(3):647–51. https://doi.org/10.1053/j.gastro.2013.12.007.CrossRefPubMed

Title: Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas
Authors: Bangbo Zhao
Qin Cheng
Hongtao Cao
Xingtong Zhou
Tianhao Li
Liangbo Dong
Weibin Wang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Cancer Biomarker
Pancreatic Cancer
Pancreatic Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08204-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma

Medical needs related to the endoscopic technology and colonoscopy for colorectal cancer diagnosis

Evaluation of functional outcome of bilateral kidney tumors after sequential surgery

ROR1 and ROR2 expression in pancreatic cancer

Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study

Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials

Keynote webinar | Spotlight on antibody–drug conjugates in cancer